
|Articles|December 22, 2010
Novartis completes Alcon acquisition.
Novartis has agreed to purchase the remaining 23% of their share in Alcon for $168 per share.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement















































